Agency Information Collection Activities; Proposed eCollection eComments Requested; Reinstatement of a Previously Approved Collection: Drug Questionnaire (DEA-341), 55689-55690 [2020-19924]
Download as PDF
<![CDATA[
55689
Federal Register / Vol. 85, No. 175 / Wednesday, September 9, 2020 / Notices
BPI in the preliminary phase of the
investigation need not reapply for such
access. A separate service list will be
maintained by the Secretary for those
parties authorized to receive BPI under
the APO.
Staff report.—The prehearing staff
report in the final phase of this
investigation will be placed in the
nonpublic record on December 22, 2020,
and a public version will be issued
thereafter, pursuant to § 207.22 of the
Commission’s rules.
Hearing.—The Commission will hold
a hearing in connection with the final
phase of this investigation beginning at
9:30 a.m. on Tuesday, January 12, 2021.
Information about the place and form of
the hearing, including about how to
participate in and/or view the hearing,
will be posted on the Commission’s
website at https://www.usitc.gov/
calendarpad/calendar.html. Interested
parties should check the Commission’s
website periodically for updates.
Requests to appear at the hearing
should be filed in writing with the
Secretary to the Commission on or
before January 7, 2021. A nonparty who
has testimony that may aid the
Commission’s deliberations may request
permission to present a short statement
at the hearing. All parties and
nonparties desiring to appear at the
hearing and make oral presentations
should participate in a prehearing
conference to be held on January 8,
2021, if deemed necessary. Oral
testimony and written materials to be
submitted at the public hearing are
governed by §§ 201.6(b)(2), 201.13(f),
and 207.24 of the Commission’s rules.
Parties must submit any request to
present a portion of their hearing
testimony in camera no later than 7
business days prior to the date of the
hearing.
Written submissions.—Each party
who is an interested party shall submit
a prehearing brief to the Commission.
Prehearing briefs must conform with the
provisions of § 207.23 of the
Commission’s rules; the deadline for
filing is January 5, 2021. Parties may
also file written testimony in connection
with their presentation at the hearing, as
provided in § 207.24 of the
Commission’s rules, and posthearing
briefs, which must conform with the
provisions of section 207.25 of the
Commission’s rules. The deadline for
filing posthearing briefs is January 20,
2021. In addition, any person who has
not entered an appearance as a party to
the investigation may submit a written
statement of information pertinent to
the subject of the investigation,
including statements of support or
opposition to the petition, on or before
VerDate Sep<11>2014
17:06 Sep 08, 2020
Jkt 250001
January 20, 2021. On February 3, 2021,
the Commission will make available to
parties all information on which they
have not had an opportunity to
comment. Parties may submit final
comments on this information on or
before February 5, 2021, but such final
comments must not contain new factual
information and must otherwise comply
with § 207.30 of the Commission’s rules.
All written submissions must conform
with the provisions of § 201.8 of the
Commission’s rules; any submissions
that contain BPI must also conform with
the requirements of §§ 201.6, 207.3, and
207.7 of the Commission’s rules. The
Commission’s Handbook on Filing
Procedures, available on the
Commission’s website at https://
www.usitc.gov/documents/handbook_
on_filing_procedures.pdf, elaborates
upon the Commission’s procedures with
respect to filings.
Additional written submissions to the
Commission, including requests
pursuant to § 201.12 of the
Commission’s rules, shall not be
accepted unless good cause is shown for
accepting such submissions, or unless
the submission is pursuant to a specific
request by a Commissioner or
Commission staff.
In accordance with §§ 201.16(c) and
207.3 of the Commission’s rules, each
document filed by a party to the
investigation must be served on all other
parties to the investigation (as identified
by either the public or BPI service list),
and a certificate of service must be
timely filed. The Secretary will not
accept a document for filing without a
certificate of service.
Authority: This investigation is being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to § 207.21 of the Commission’s
rules.
By order of the Commission.
Issued: September 2, 2020.
Lisa Barton,
Secretary to the Commission.
Drug Enforcement Administration
[Docket No. DEA–704]
Bulk Manufacturer of Controlled
Substances Application: Nanosyn Inc.
Frm 00054
Fmt 4703
Sfmt 4703
Controlled substance
Oxymorphone ................
Fentanyl .........................
Drug
code
9652
9801
Schedule
II
II
The company is a contract
manufacturer. At the request of the
company’s customers, it manufactures
derivatives of controlled substances in
bulk form.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–19868 Filed 9–8–20; 8:45 am]
BILLING CODE P
[OMB Number 1117–0043]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Reinstatement
of a Previously Approved Collection:
Drug Questionnaire (DEA–341)
DEPARTMENT OF JUSTICE
PO 00000
In
accordance with 21 CFR 1301.33(a), this
is notice that on August 6, 2020,
Nanosyn Inc., 3331 Industrial Drive,
Suite B, Santa Rosa, California 95403–
2062, applied to be registered as an bulk
manufacturer of the following basic
class(es) of controlled substances:
SUPPLEMENTARY INFORMATION:
Drug Enforcement Administration
BILLING CODE 7020–02–P
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before November 9, 2020. Such
persons may also file a written request
for a hearing on the application on or
before November 9, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
DEPARTMENT OF JUSTICE
[FR Doc. 2020–19831 Filed 9–8–20; 8:45 am]
AGENCY:
Nanosyn Inc. has applied to
be registered as a bulk manufacturer of
basic class(es) of controlled substances.
Refer to Supplemental Information
listed below for further drug
information.
SUMMARY:
Drug Enforcement
Administration, Department of Justice.
ACTION: 60-Day notice.
AGENCY:
The Drug Enforcement
Administration, Department of Justice
(DOJ), will be submitting the following
information collection request to the
Office of Management and Budget
(OMB) for review and approval in
SUMMARY:
E:\FR\FM\09SEN1.SGM
09SEN1
55690
Federal Register / Vol. 85, No. 175 / Wednesday, September 9, 2020 / Notices
accordance with the Paperwork
Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 60 days until
November 9, 2020.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Sharyn J. Saunders, Assistant
Administrator, 202–307–6287, Human
Resources Division, Drug Enforcement
Administration, 8701 Morrissette Drive,
Springfield, VA 22152.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
1. Type of Information Collection:
Extension of a previously approved
collection.
2. The Title of the Form/Collection:
Drug Use Statement.
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
The form number is the DEA–341. The
sponsoring component is the Drug
Enforcement Administration.
4. Affected public who will be asked
or required to respond, as well as a brief
abstract: The affected public is Drug
Enforcement Administration applicants.
DEA is requesting an extension of a
VerDate Sep<11>2014
17:06 Sep 08, 2020
Jkt 250001
previously approved collection. This
collection requires the drug history of
any individual seeking employment
with DEA. DEA policy states that a past
history of illegal drug use may result in
ineligibility for employment. The form
asks job applicants specific questions
about their personal history, if any, of
illegal drug use.
5. An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that 15,000
respondents will complete the
application in approximately 5 minutes.
6. An estimate of the total public
burden (in hours) associated with the
collection: The estimated public burden
associated with this collection is 1,250
hours. It is estimated that applicants
will take 5 minutes to complete the
questionnaire. (15,000 respondents × 5
minutes = 75,000 hours. 75,000/60
seconds = 1,250 hrs.).
If additional information is required
contact: Melody Braswell, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE, 3E.405B,
Washington, DC 20530.
Dated: September 3, 2020.
Melody Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2020–19924 Filed 9–8–20; 8:45 am]
BILLING CODE 4410–14–P
DEPARTMENT OF JUSTICE
Foreign Claims Settlement
Commission
[F.C.S.C. Meeting and Hearing Notice No.
07–20]
Sunshine Act Meetings
The Foreign Claims Settlement
Commission, pursuant to its regulations
(45 CFR part 503.25) and the
Government in the Sunshine Act (5
U.S.C. 552b), hereby gives notice in
regard to the scheduling of open
meetings as follows:
TIME AND DATE: Thursday, September 17,
2020, at 10:00 a.m.
PLACE: This meeting will be held by
teleconference. There will be no
physical meeting place.
STATUS: Open. Members of the public
who wish to observe the meeting via
teleconference should contact Patricia
M. Hall, Foreign Claims Settlement
Commission, Tele: (202) 616–6975, two
business days in advance of the
meeting. Individuals will be given call-
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
in information upon notice of
attendance to the Commission.
MATTERS TO BE CONSIDERED: 10:00 a.m.—
Issuance of Proposed Decisions under
the Guam World War II Loyalty
Recognition Act, Title XVII, Public Law
114–328.
CONTACT PERSON FOR MORE INFORMATION:
Requests for information, advance
notices of intention to observe an open
meeting, and requests for teleconference
dial-in information may be directed to:
Patricia M. Hall, Foreign Claims
Settlement Commission, 441 G St. NW,
Room 6234, Washington, DC 20579.
Telephone: (202) 616–6975.
Brian M. Simkin,
Chief Counsel.
[FR Doc. 2020–19964 Filed 9–4–20; 11:15 am]
BILLING CODE 4410–BA–P
MILLENNIUM CHALLENGE
CORPORATION
[MCC FR 20–05]
Notice of Open Meeting
Millennium Challenge
Corporation.
ACTION: Notice.
AGENCY:
In accordance with the
requirements of the Federal Advisory
Committee Act, the Millennium
Challenge Corporation (MCC) Economic
Advisory Council was established as a
discretionary advisory committee on
October 5, 2018. The MCC Economic
Advisory Council serves MCC in an
advisory capacity only and provides
advice and guidance to MCC
economists, evaluators, leadership of
the Department of Policy and
Evaluation, and senior MCC leadership
regarding relevant trends in
development economics, applied
economic and evaluation methods,
poverty analytics, as well as modeling,
measuring, and evaluating development
interventions. In doing so, the MCC
Economic Advisory Council helps
sharpen MCC’s analytical methods and
capacity in support of the agency’s
economic development goals. It also
serves as a sounding board and
reference group for assessing and
advising on strategic policy innovations
and methodological directions in MCC.
DATES: Friday, September 25th, 2020,
from 10:00 a.m.–12:00 p.m. ET.
ADDRESSES: The meeting will be held
via conference call.
FOR FURTHER INFORMATION CONTACT:
Mesbah Motamed, 202.521.7874,
MCCEACouncil@mcc.gov or visit
SUMMARY:
E:\FR\FM\09SEN1.SGM
09SEN1
]]>Agencies
[Federal Register Volume 85, Number 175 (Wednesday, September 9, 2020)]
[Notices]
[Pages 55689-55690]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-19924]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[OMB Number 1117-0043]
Agency Information Collection Activities; Proposed eCollection
eComments Requested; Reinstatement of a Previously Approved Collection:
Drug Questionnaire (DEA-341)
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: 60-Day notice.
-----------------------------------------------------------------------
SUMMARY: The Drug Enforcement Administration, Department of Justice
(DOJ), will be submitting the following information collection request
to the Office of Management and Budget (OMB) for review and approval in
[[Page 55690]]
accordance with the Paperwork Reduction Act of 1995.
DATES: Comments are encouraged and will be accepted for 60 days until
November 9, 2020.
FOR FURTHER INFORMATION CONTACT: If you have additional comments
especially on the estimated public burden or associated response time,
suggestions, or need a copy of the proposed information collection
instrument with instructions or additional information, please contact
Sharyn J. Saunders, Assistant Administrator, 202-307-6287, Human
Resources Division, Drug Enforcement Administration, 8701 Morrissette
Drive, Springfield, VA 22152.
SUPPLEMENTARY INFORMATION: Written comments and suggestions from the
public and affected agencies concerning the proposed collection of
information are encouraged. Your comments should address one or more of
the following four points:
--Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the agency, including
whether the information will have practical utility;
--Evaluate the accuracy of the agency's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used;
--Evaluate whether and if so how the quality, utility, and clarity of
the information to be collected can be enhanced; and
--Minimize the burden of the collection of information on those who are
to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submission of responses.
Overview of This Information Collection
1. Type of Information Collection: Extension of a previously
approved collection.
2. The Title of the Form/Collection: Drug Use Statement.
3. The agency form number, if any, and the applicable component of
the Department sponsoring the collection: The form number is the DEA-
341. The sponsoring component is the Drug Enforcement Administration.
4. Affected public who will be asked or required to respond, as
well as a brief abstract: The affected public is Drug Enforcement
Administration applicants. DEA is requesting an extension of a
previously approved collection. This collection requires the drug
history of any individual seeking employment with DEA. DEA policy
states that a past history of illegal drug use may result in
ineligibility for employment. The form asks job applicants specific
questions about their personal history, if any, of illegal drug use.
5. An estimate of the total number of respondents and the amount of
time estimated for an average respondent to respond: It is estimated
that 15,000 respondents will complete the application in approximately
5 minutes.
6. An estimate of the total public burden (in hours) associated
with the collection: The estimated public burden associated with this
collection is 1,250 hours. It is estimated that applicants will take 5
minutes to complete the questionnaire. (15,000 respondents x 5 minutes
= 75,000 hours. 75,000/60 seconds = 1,250 hrs.).
If additional information is required contact: Melody Braswell,
Department Clearance Officer, United States Department of Justice,
Justice Management Division, Policy and Planning Staff, Two
Constitution Square, 145 N Street NE, 3E.405B, Washington, DC 20530.
Dated: September 3, 2020.
Melody Braswell,
Department Clearance Officer for PRA, U.S. Department of Justice.
[FR Doc. 2020-19924 Filed 9-8-20; 8:45 am]
BILLING CODE 4410-14-P
